These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27510853)

  • 1. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
    Palandri F; Auteri G; Baccarani M
    Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving treatment paradigm in myelofibrosis.
    Mesa RA
    Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating early-stage myelofibrosis.
    Palandri F; Sabattini E; Maffioli M
    Ann Hematol; 2019 Feb; 98(2):241-253. PubMed ID: 30343328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing new therapies and their overall impact in myelofibrosis.
    Mesa RA
    Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelofibrosis: clinicopathologic features, prognosis, and management.
    O'Sullivan JM; Harrison CN
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 inhibitors: A reality? A hope?
    Apostolidou E; Kantarjian HM; Verstovsek S
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S340-5. PubMed ID: 19778862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches in myelofibrosis.
    Barosi G; Rosti V; Vannucchi AM
    Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
    Kekre N; Ho VT
    Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
    Verstovsek S
    Clin Cancer Res; 2010 Apr; 16(7):1988-96. PubMed ID: 20215535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostication in MF: from CBC to cytogenetics to molecular markers.
    Zhou A; Oh ST
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.